Leap Therapeutics’ Post

We know that testing is important to personalize and select therapy. In this study, what we found was amongst patients who had results available prior to first-line therapy had significant improvements in survival compared with patients who did not have results available. This was an important finding because if we can use a test to impart a survival advantage, we should be using it.

Most immunotherapy trials in the metastatic setting cease treatment at two years. Extending ICI treatment beyond two years also increases the risk of medical and financial toxicity. However, is there any benefit to extending IO beyond two years? Read more: https://lnkd.in/g_jqCb_U

ctDNA or MRD guided therapy has not yet made its way into clinical guidelines, but it is becoming more commonly used in clinical practice. For example, there has been early data showing that a ctDNA guided approach at least does not worsen relapse-free survival in patients.  Protocols for many ctDNA guided clinical trials are available, so it is easy for clinicians to bring these strategies to the community by simply copying the protocol.  However, is this appropriate?  We have to remember that there is no strong phase III data supporting the predictive power of ctDNA-guided treatment. In MRD, many of the published clinical trials used substandard standard-of-care arms.   While under treatment based on a negative ctDNA/MRD may lead to earlier relapse, overtreatment on a positive ctDNA/MRD can worsen quality of life without additional benefit. Until strong phase 3 data comes out, we should wait on bringing this biomarker into clinical practice. #ctdna  #mrd https://lnkd.in/emztJc4W

#Erdafitinib for #UrothelialCancer. What can we learn from the two cohorts of the #THOR trial? Read Viewpoint in #Med https://lnkd.in/erYH6uTT

A recent analysis of safety data from the PAOLA-1 study was used to develop recommendations on clinical management of key side effects with olaparib plus bevacizumab as frontline therapy for patients with advanced #ovariancancer. #gyncsm

More than 75% of cancer patients prescribed an oral treatment must overcome a rejection through their insurer- this results in delays of 2-3 weeks on average for initiation. Access challenges in oncology continue to evolve – please read this white paper from my colleagues Jeff Thiesen, Ruthy Glass, PhD and Claudia Lamprecht to read more about the landscape of access barriers and how the IRA may even drive increased controls.   👉White paper included here: https://lnkd.in/eVCde-Zb

Herein, authors discuss #deliverytechnologies that have the potential to reduce various clinical barriers for in situ #cancervaccines. https://lnkd.in/g4EAS72U

#ESMOBreast24: TROPION-Breast01, datopotamab deruxtecan (Dato-DXd) w/ previously treated HR+/HER2- metastatic #BC demonstrated: ✅ 21% rate of grade ≥3 TRAEs vs 45% w/ chemotherapy ✅ Median treatment duration of 6.7 months vs 4.1 months w/ chemotherapy These results suggest that Dato-DXd offers an improved safety profile and treatment duration compared to standard chemotherapy 👇To learn more, read the #ESMODailyReporter article https://ow.ly/UVeB50RIqrF

Really positive news that diagnostics are improving patient treatment. Here circulating tumour DNA was detected helping to identify the best drug for the patient. Once the best drug has been identified, do you think a more personalised dose would improve treatment further, rather than a one-size-fits-all dose? By adjusting dosing to reach target concentrations, toxicity could be reduced and bioavailability increased - making sure there is enough to treat the disease but not too much. With drug costs as high as £5,000 a month per patient, more precise treatments could also save money for healthcare services/goverments/tax payers. https://lnkd.in/eSkJ2rFm

A study will evaluate elenestinib as monotherapy and in combination with azacitidine in patients with advanced #systemicMastocytosis.